Aggregopathy in Neurodegenerative Diseases: Mechanisms and Therapeutic Implication
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Many neurodegenerative diseases such as Parkinson’s, Alzheimer’s, Huntington’s and Lou Gehrig’s disease are associated with the misfolding and aggregation of proteins. While the relevance of these aggregates for neuronal degeneration and their impact on cellular function is still a matter of debate, several experimental therapeutic approaches have been aimed at interfering with protein aggregation. In this review, we want to summarize the current understanding of aggregate formation and toxicity in neurodegenerative diseases with an emphasis on Parkinson’s disease. Furthermore, we will discuss current treatment strategies in these diseases targeting aggregate formation and concurrent neuronal cell death in these diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454 · cited 1×
“The long lifetime of postmitotic neurons under extreme metabolic conditions through high oxygen utilization and neurotransmitter production makes them especially vulnerable to aggregation-related alterations. There is no concerted nomenclature for aggregates and their soluble oligomeric intermediates. Several differen…”
BackgroundA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 1×
“Dysfunction of the ubiquitin-proteasome pathway with impaired degradation of misfolded proteins is an important common feature in aggregopathies and is thought to contribute substantially to pathogenesis. Because of the central role of the UPS in a large number of different processes in the cell, the development of dr…”
BackgroundTransplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024
Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin
Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., Yoo, S. J., Hay, B. A., & Guo, M. (2006) · Nature · doi:10.1038/nature04779 · Cited by 1,788 · cited 1×
“whereas PINK1 mutation results in defects of mitochondrial morphology and increased sensitivity to multiple stresses including oxidative stress in vivo [”
BackgroundMice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
Caughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650 · cited 1×
“for review). How SOD1 mutations lead to motor neuron degeneration remains unclear. By now, more than 100 mutations have been identified that do not uniformly affect SOD1 enzyme activity but show a dose-related effect with rapidly progressive disease in homozygous patients (see [”
BackgroundAβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease
Auluck, P. K., Chan, H. Y. E., Trojanowski, J. Q., Lee, V. M.-Y., & Bonini, N. M. (2002) · Science · doi:10.1126/science.1067389 · Cited by 1,227
Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct
Conway, K. A., Rochet, J.-C., Bieganski, R. M., & Lansbury, P. T. (2001) · Science · doi:10.1126/science.1063522 · Cited by 1,127
Cited by
Luciani, A., Villella, V. R., Esposito, S., Brunetti-Pierri, N., Medina, D., Settembre, C., Gavina, M., Pulze, L., Giardino, I., Pettoello-Mantovani, M., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2090 · Cited by 467
“The accumulation of unwanted/misfolded protein aggregates has been described in several human disorders, such as neurodegenerative disease”
BackgroundVeeriah, S., Taylor, B. S., Meng, S., Fang, F., Yilmaz, E., Vivanco, I., Janakiraman, M., Schultz, N., Hanrahan, A. J., Pao, W., et al. (2010) · Nature Genetics · doi:10.1038/ng.491 · Cited by 406
Villella, V. R., Esposito, S., Bruscia, E. M., Maiuri, M. C., Raia, V., Kroemer, G., & Maiuri, L. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00001 · Cited by 389
Casarejos, M. J., Solano, R. M., Gómez, A., Perucho, J., de Yébenes, J. G., & Mena, M. A. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.01.008 · Cited by 114
“Neurodegenerative diseases like Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD) are characterized by abnormal accumulation of different proteins in neurons and glia (Dohm et al., 2008; Enokido et al., 2010; McMillan and Leverenz, 2010; Nakamura and Lipton, 2010).”
BackgroundThe neuroprotective effect of doxycycline on neurodegenerative diseases
Santa-Cecília, F. V., Leite, C. A., Del-Bel, E., & Raisman-Vozari, R. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00015-z · Cited by 73
Metadata
- Authors
- Dohm, C. P., Kermer, P., & Bähr, M.
- Venue
- Neurodegenerative Diseases
- Publisher
- S. Karger AG
- Published
- 2008
- Volume
- 5
- Issue
- 6
- Pages
- 321-338
- ISSN
- 1660-2854 (ISSN-L)
- 1660-2862
- OpenAlex
- W2049571824
- Cited by
- 54
- References
- 25
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aggregopathy in Neurodegenerative Diseases: Mechanisms and Therapeutic Implication. https://app.cochat.ai/papers/10.1159/000119459
- The paper
- Dohm, C. P., Kermer, P., & Bähr, M. (2008). Aggregopathy in Neurodegenerative Diseases: Mechanisms and Therapeutic Implication. Neurodegenerative Diseases. https://doi.org/10.1159/000119459
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.